Abviva, Inc. was established to develop and commercialize diagnostic and therapeutic products from a novel breast cancer growth inhibitory protein. Research scientists at the prestigious University of Michigan Cancer Center discovered a secreted protein produced in normal breast epithelial cells that inhibits the growth of breast cancer.

1. Diagnostic and Therapeutic Innovation
Abviva, Inc.
402 East Gutierrez Street
Santa Barbara, CA 93101
t: 800.970.5870 | f: 800.970.5874
www.abviva.com

2. FORWARD LOOKING STATEMENTS
Statements in this presentation that are not strictly historical facts are
“forward looking” statements (identified by the words “believe”,
“estimate”, “project”, “expect” or similar expressions) within the meaning
of the Private Securities Litigation Reform Act of 1995. These statements
inherently involve risks and uncertainties that could cause actual results to
differ materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not limited to,
continued acceptance of the Company’s products and services in the
marketplace, competitive factors, changes in the regulatory environment,
and other risks detailed in the Company’s periodic report filings with the
Securities and Exchange Commission. The statements in this presentation
are made as of today, based upon information currently known to
management, and the Company does not undertake any obligation to
publicly update or revise any forward-looking statements.

3. Mammastatin Serum Assay
 Breast Cancer Risk Assessment
 Mammastatin Serum Assay (MSA)
 MSA Is A Simple Blood Test
 Clinical Studies Demonstrate Value
 Patented Technology
 Exclusive License
 MSA Assay Developed
 Commercialize Current MSA - CLIA
 $3.3 Billion US Addressable Market

4. Mammastatin Serum Assay
Favorable PSA Assay Statistical Comparison
Negative Positive
Screening Test Sensitivity Specificity Predictive Predictive Accuracy
Value Value
Mammastatin Serum
Assay (MSA)
71% 86% 98% 25% 85%
Prostate-Specific
Antigen Assay (PSA)
68% - 80% 60% - 70% 98% 30% 67%
PSA Assay Statistical Performance References:
“Prostate-Specific Antigen (PSA) Best Practice Policy” Oncology Vo. 14, No 2 (February 6, 2000)
“Predictors of Prostate Carcinoma: Accuracy of Gray-Scale and Color Doppler US and Serum Markers” Radiology. 2001; 220: 757-764
“Prostate Screening – Learn More: Accuracy of the PSA Test” http://www.realage.com/health_guides/ProstateCancer/topics/fs_topics.asp?memberId=&cbr=&topic=23

5. Mammastatin Science
 Science Of Mammastatin:
 Normally Present In Healthy Women
 Secreted From Breast Epithelial Cells
 Inhibits Growth of Breast Cancer Cells
 Detected In Peripheral Blood Serum
 Published In Scientific Journals
 Science 1989
 IVD Technology – MSA – 2003
 High Levels (Normal) ~ Low Risk
 Low Levels (Not Normal) ~ High Risk

6. Mammastatin US Patent Portfolio
ISSUED US
PATENTS PATENT NAME
6,451,765 Methods for Treating Breast Cancer Using Mammastatin
6,492,504 Nucleotide Sequence of Mammastatin and Methods of Use
6,500,937 Nucleotide Sequence Encoding a Mammary Cell Growth Inhibitor
6,599,495 Nucleotide and Protein Sequence of Mammastatin and Methods of Use
7,256,277 Nucleotide and Protein Sequence of Mammastatin and Methods of Use
7,323,173 Methods for Treating Breast Cancer Using a Mammary Cell Growth Inhibitor
7,332,287 Methods and Compositions for Diagnosing Breast Cancer

7. Breast Cancer Screening Market
 No Equivalent Risk Assessment Test Available Today
 Simple, Cost Effective Broad-Based Population Screening
 Global Market Potential:
 US Target Market:
 82 Million Women Over 30
 500 Million Women Worldwide*
 US Addressable Market:
 Women > 30 Yrs. Getting Annual Mammograms
 48 Million in US
 Over $3.3 Billion US Addressable Market
 Predictive Screening Growing In Popularity
 Benefits Of Earlier Breast Cancer Detection:
 Higher Survival Rate – Up To 98%
 Reduction In Death Rate
 Lower Health Care Costs
• Women With Access To Health Care
• National Health Interview Survey Public Use Data File 2005, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006;
• American Cancer Society, Surveillance Research, 2007
• Breast Cancer Facts & Figures 2007 – 2008; American Cancer Society
• Algood et al. (2007) British Journal of Cancer

8. Breast Cancer Testing
Breast Type Use Benefits Disadvantages Cost
Cancer Test
Mammogram Diagnostic Identifies Masses For  Screening Standard  Radiation Exposure $100 - $150
Imaging Follow Up and Biopsy To  Identifies Masses  False Positives
Confirm Breast Cancer  Difficult On Dense Breasts
Ultrasound Diagnostic Identify Masses For Follow  Adjunct To Mammography  Not Mammogram Substitute $150 - $450
Imaging Up and Biopsy To Confirm  Preferred For Dense  Limited Access Early In
Breast Cancer Breasts Adoption Cycle
 Lower False Positive Rate
MRI Diagnostic Identifies Masses For  High Resolution  Radiation Exposure $1,000 - $1,500
Imaging Follow Up and Biopsy To  Better Identification  Many False Positives
Confirm Breast Cancer  Pin-point accuracy  Costly
BRCA-1; BRCA-2 Genetic Test – Positive result indicates  Blood Test  1 in 800 people have gene $300 - $3,000
Blood Test mutations in BRCA gene  Accurate if gene present  Genetic Screening Issues
associated with breast  Positive Indicates High  Negative test does not rule
cancer predisposition Risk out breast cancer
Her-2/neu Tumor Marker- Indicates how aggressive  Specific for Her-2/neu  After Cancer Diagnosed $50 - $100
Blood Test breast cancer may be, and positive breast cancer  < 12% of breast cancers
indicates Herceptin  Rresponse to Herceptin  Not adequate for screening
treatment  Blood test
Oncotype Dx Test Estrogen Sets guidelines for hormone  Indicates therapies if tumor  Tissue Sample $3,500
Receptor Test therapy, and evaluates risk influenced by hormones  Not adequate for screening
– Tissue Test of cancer recurrence  Use After Cancer Diagnosed
Mammastatin Blood Test Measure mammastatin High  Simple Blood Test  Pre-Launch Assay $150
Serum Assay Levels = Low Risk  Identify High Risk Women  Early Clinical Validation
Low Levels = High Risk  Efficacy Demonstrated  Mammastatin Mechanism of
 Universal Screening Action Uncertain
Access  CLIA Only Test Today
Therapeutic Monitoring  Initially Private Pay
Test for future mammastatin
drug

9. Commercial Development Timeline
2010 2011 2012 2013 2014 2015
Launch Current MSA Test
Retrospective Study
Commercial Launch
ASR Designation
Submit ASR Application
FDA Approval
Lab Partner & National Distribution
FDA MSA PMA
File PMA I (Mfn.) Start Clinicals
File PMA II (Data)
File Original PMA
FDA Approval
Insurance Reimbursement
International Distribution
FDA MSA Test Kit 510(k)
Test Kit Developed
Clinical Studies
File 510(k)
FDA Approval

10. Breast Cancer Diagnostic Test
 Mammastatin Serum Assay (MSA)
 Operating and Financial Targets*:
 Revenue in 2nd Quarter 2011
 Positive Cash Flow in 2011
 Accelerated Growth Rate in Year 3
 Year 5 Targets*:
 + $200 mm Revenue
 Sustainable Double Digit Earnings
 Market Value ~ 25 to 35 P/E Multiple

11. MSA Test Summary
 Patented Breast Cancer Risk Assessment Diagnostic
 Addresses Unmet Medical Need
 Large Global Market Opportunity
 Initial Diagnostic Technology Validated
 Serum MSA Test Ready for Commercialization
 Well Defined, Achievable Commercial Development
 High Value Commercial Opportunity

12. Mammastatin Breast Cancer Therapy
 Protein Present In Healthy Women
 Secreted From Breast Epithelial Cells
 Early Protein Replacement Therapy
 29 Women Treated - Compassionate Use
 Compelling Patient Results
 Palliative Stage IV Breast Cancer Patients
 Physical Health of Women Improved
 Metastatic Tumor Reduction – Bone Scans
 Lives Extended Months to Years
 Women Survived On Therapy Until Study Ended
 Up To Two+ Year Survival After Therapy Initiated
 All Expired Within 6 Months After Studies Ended

13. Development Milestones
 Re-Establish Biologic Activity In Cell Culture
 Ablation Study - Same Monoclonal Ab As MSA Assay
 Development Concurrent With MSA Development
 Develop Recombinant Protein
 Manufacturing Through Phase I/II
 Complete Pre-Clinical Studies
 Submit To FDA For Accelerated Status
 Initiate Phase I/II Trials

14. Rationale For Rx Development
 Published Research: Protein Secreted By Breast Epithelial Cells
 Published Research: Strong Anti-Cancer Growth Inhibition
 Human Dx Studies: Protein Normally Present In Women
 Human Dx Studies: Protein Absent In Breast Cancer
 Human Rx Studies: Compassionate Use on 29 Women
 Human Rx Studies: Lives Extended During Therapy
 Human Rx Studies: Metastatic Tumors Reduced (Bone Scan)
 Physician Observations: Patient Overall Health Improved
 Physician Observations: Placebo Effect Impossible

15.  Commercial Stage Breast Cancer Risk Assessment
 Breast Cancer Therapeutic Drug Demonstrated
 Concomitant Therapeutic Monitoring Assay
 Exclusive IP & Patent Protection
 Diagnostic Products At Commercial Stage
 Experienced Management
 MSA Revenues in 2011 *
 Address Large Global Markets & Unmet Needs
 Large Capital Appreciation Potential
* Assumes Financing in Q3 2010

16. Corporate Structure and Management
Executive and Financial Management
Business Development
Financing and Liquidity
Breast Cancer Risk Assessment Diagnostic Incorporate In 2011
A Wholly Owned Subsidiary Develop Mammastatin Therapeutic Assets
Mammastatin Serum Assay Business

17. www.abviva.com
Abviva, Inc.
402 East Gutierrez Street
Santa Barbara, CA 93101
t: 800.970.5870 | f: 800.970.5874
www.abviva.com